Transcutaneous tibial nerve stimulation for the treatment of bladder dysfunction in patients with neurological disorders: A randomized, sham-controlled, double-blind clinical study.
Descrizione riassuntiva dello studio
Bladder dysfunction is common in patients with a neurological disorder (so-called neurogenic bladder dysfunction) and can limit quality of life as well as lead to long-term kidney damage. Treatments with medications often do not lead to sufficient improvement of symptoms and/or have bothersome side effects. Tibial nerve stimulation therapy (nerve located behind the inner ankle) offers a potentially well-tolerated treatment method. A self-adhesive skin electrode is placed behind the inner ankle and an electrode on the arch of the foot. A low-voltage stimulator (9 volts) stimulates the tibial nerve for 30 minutes. The electrical impulses are transmitted via the tibial nerve to the spinal cord, which is important for bladder control, and lead, with repeated application, to an improvement in bladder symptoms in many patients. Although the exact mechanisms are not fully understood, the repeated performance of this type of electrical stimulation therapy is particularly important for the success of the treatment. Experience shows that a noticeable improvement is only observed after approximately 6 stimulations, so treatment cycles with 12 stimulations have become established. This type of electrical stimulation therapy has proven effective in patients without neurological disorders and offers an excellent and almost side-effect-free alternative to treatments such as Botox injections into the bladder muscle or surgeries on the bladder. The aim of the study is to investigate the benefits of tibial nerve stimulation therapy in patients with bladder dysfunction due to neurological disorders.
(BASEC)
Intervento studiato
Patients who meet the inclusion criteria and agree to participate in the study will be randomly assigned (randomization) to the treatment or sham treatment group. Patients in both groups will be connected for 30 minutes to a low-voltage stimulator (9 volts) ELPHA II 3000 (Danmeter S/A) via skin electrodes on the foot, twice a week for 6 weeks (a total of 12 sessions). The device settings will be made by a medical professional, who will be the only one to know the group allocation of the participants. Neither the study participant nor the medical professionals who will assess the study results will know in which group the participant is. On the days between the stimulation sessions, participants will be asked to keep a bladder diary, i.e., to document the times and amounts of fluid intake and urine output, as well as involuntary urine losses and pad usage. At every second session, patients will be asked to fill out a questionnaire on urinary incontinence, bladder symptoms and bladder perception, sexual and bowel function, and quality of life. After the last TTNS session (total of 12 TTNS sessions, 2 per week, i.e., 6 weeks in total), a clinical follow-up will take place within one week with a urine test, bladder diary, questionnaires on urinary incontinence, bladder symptoms and bladder perception, sexual and bowel function, quality of life, as well as urodynamics and neurophysiological follow-up.
(BASEC)
Malattie studiate
Patients in whom bladder dysfunction due to a neurological disorder (e.g., multiple sclerosis, Parkinson's disease, spinal cord injury, etc.) has been diagnosed through bladder pressure measurement (urodynamics), accompanied by strong urgency, urine loss, and/or incomplete emptying of the bladder.
(BASEC)
- Women and men - Age 18 years or older - Written consent of the participating person - Last urethra-cystoscopy and bladder wash cytology within 1 year - Last urodynamic examination within 6 months and no changes in bladder medication - Bladder dysfunction due to a neurological disorder, which has not responded to medications: - Strong urgency with/or involuntary urine loss (medication with at least 2 anticholinergics for at least 4 weeks) - Incomplete emptying of the bladder (medication with an alpha-blocker for at least 4 weeks) - Combination of both disorders (medication with at least 2 anticholinergics for at least 4 weeks and an alpha-blocker for at least 4 weeks) - Motor response to TTNS stimulation in at least one leg (BASEC)
Criteri di esclusione
- Botulinum toxin A injections into the bladder muscle and/or sphincter in the past 6 months - Neuromodulative therapy in the last 6 months or currently - Age < 18 years - Pregnancy - Particularly vulnerable individuals (According to the guidelines on research involving humans of the Swiss Academy of Medical Sciences) - Inability of the patient to follow the trial procedures, e.g., due to language problems, mental illnesses, dementia, etc. (BASEC)
Luogo dello studio
Aarau, Basilea, Bellinzona, Berna, Losanna, San Gallo, Winterthur, Zurigo
(BASEC)
Sponsor
non disponibile
Contatto per ulteriori informazioni sullo studio
Persona di contatto in Svizzera
Thomas M. Kessler
+41 44 386 39 07
thomas.kessler@clutterbalgrist.ch(BASEC)
Informazioni scientifiche
non disponibile
Nome del comitato etico approvante (per studi multicentrici solo il comitato principale)
Commissione etica Zurigo
(BASEC)
Data di approvazione del comitato etico
25.10.2016
(BASEC)
ID di studio ICTRP
NCT02859844 (ICTRP)
Titolo ufficiale (approvato dal comitato etico)
non disponibile
Titolo accademico
non disponibile
Titolo pubblico
Transcutaneous Tibial Nerve Stimulation for Treating Neurogenic Lower Urinary Tract Dysfunction (ICTRP)
Malattie studiate
Neurogenic Bladder Dysfunction
(ICTRP)
Intervento studiato
Device: Transcutaneous Tibial Nerve Stimulation (TTNS)
(ICTRP)
Tipo di studio
Interventional (ICTRP)
Disegno dello studio
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor). (ICTRP)
Criteri di inclusione/esclusione
Inclusion Criteria:
- Refractory LUTD due to a neurological disorder:
- Urgency frequency syndrome and/or urgency incontinence refractory to antimuscarinics
(pharmacotherapy for at least 4 weeks with at least 2 antimuscarinics)
- Chronic urinary retention refractory to alpha-blocker (pharmacotherapy with an
alpha-blocker for at least 4 weeks)
- Combination of urgency frequency syndrome and/or urgency incontinence and chronic
urinary retention refractory to antimuscarinics (pharmacotherapy for at least 4 weeks
with at least 2 antimuscarinics) and alpha-blocker (pharmacotherapy with an
alpha-blocker for at least 4 weeks)
- Age >18 years
- Informed consent
Exclusion Criteria:
- Botulinum A toxin injections in the detrusor and/or urethral sphincter in the last 6
months
- Age <18 years
- Pregnancy
- Individuals especially in need of protection (according to Research with Human
Subjects published by the Swiss Academy of Medical Sciences
www.samw.ch/en/News/News.html)
- No informed consent
(ICTRP)
non disponibile
Endpoint primari e secondari
Number of leakages
Number of used pads
Number of voids
Post void residual (mL)
(ICTRP)
non disponibile
Data di registrazione
30.06.2016 (ICTRP)
Inclusione del primo partecipante
01.10.2016 (ICTRP)
Sponsor secondari
non disponibile
Contatti aggiuntivi
non disponibile
ID secondari
2016-01016 (ICTRP)
Risultati-Dati individuali dei partecipanti
non disponibile
Ulteriori informazioni sullo studio
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT02859844 (ICTRP)
Risultati dello studio
Riepilogo dei risultati
non disponibile
Link ai risultati nel registro primario
non disponibile